

Sterling Biotech Limited  
Registered Office : 43, Atlanta Building, Nariman Point, Mumbai - 400021.

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST DECEMBER, 2008**

(Rs.in Lacs)

Sr. No.	Particulars	3 months ended	Corresponding 3	For the Year	For the Year
		31/12/2008	months ended	Ended	Ended
		Unaudited	31/12/2007	31/12/2008	31/12/2007
			Unaudited	Audited	Audited
1	Income				
	a) Net Sales/Income from Operations	33,073.20	26,129.52	117,838.07	91,084.76
	b) Other Operating Income	236.18	262.97	1,003.26	995.84
	<b>c) Total</b>	<b>33,309.38</b>	<b>26,392.49</b>	<b>118,841.33</b>	<b>92,080.60</b>
2	Expenditure				
	a) (Increase)/decrease in stock in trade and work in progress	848.26	417.92	313.09	(5,746.29)
	b) Consumption of raw materials	12,334.88	8,949.63	42,153.95	37,352.61
	c) Employees Cost	944.19	936.78	3,522.48	2,437.42
	d) Depreciation	2,881.30	2,151.30	10,715.18	8,625.97
	e) Other expenditure	6,292.13	4,641.62	21,718.36	16,175.81
	<b>f) Total</b>	<b>23,300.76</b>	<b>17,097.25</b>	<b>78,423.06</b>	<b>58,845.52</b>
3	Profit from Operations before Other Income and Interest (1-2)	10,008.62	9,295.24	40,418.27	33,235.08
4	Other Income	0.00	0.00	0.00	0.00
5	Profit before Interest (3+4)	10,008.62	9,295.24	40,418.27	33,235.08
6	Interest	2,442.31	1,097.32	5,920.71	4,135.20
7	<b>Profit (+) / Loss (-) from Ordinary Activities before tax (5-6)</b>	<b>7,566.31</b>	<b>8,197.92</b>	<b>34,497.56</b>	<b>29,099.88</b>
8	Tax expense				
	a) Current	750.00	935.00	3,750.00	3,150.00
	b) Deffered	1,850.00	2,100.00	7,550.00	6,350.00
	c) Fringe Benefit	12.50	22.01	47.50	40.00
	<b>d) Total</b>	<b>2,612.50</b>	<b>3,057.01</b>	<b>11,347.50</b>	<b>9,540.00</b>
9	<b>Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)</b>	<b>4,953.81</b>	<b>5,140.91</b>	<b>23,150.06</b>	<b>19,559.88</b>
10	Extraordinary Items	283.16	209.25	1,132.64	1,010.76
11	<b>Net Profit (+)/Loss (-) for the period (9-10)</b>	<b>4,670.65</b>	<b>4,931.66</b>	<b>22,017.42</b>	<b>18,549.12</b>
12	Prior year adjustment	99.29	0.00	99.29	178.59
13	<b>Profit available for appropriation</b>	<b>4,571.36</b>	<b>4,931.66</b>	<b>21,918.13</b>	<b>18,370.53</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,437.98	2,294.76	2,437.98	2,294.76
15	Reserves excluding Revaluation Reserves as per balance sheet.			170,359.64	126,895.57
16	Earnings Per Share (EPS)				
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	2.03	2.24	9.50	8.52
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.92	2.15	9.03	8.08
17	Public Shareholding				
	- Number of shares	127,267,548	124,007,515	127,267,548	124,007,515
	- Percentage of shareholding	52.20%	54.04%	52.20%	54.04%
18	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	Number of shares	32,488,136		32,488,136	
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	36.49%		36.49%	
	Percentage of shares (as a % of the total share capital of the Company)	13.33%		13.33%	
	b) Non-encumbered				
	Number of shares	56,546,558		56,546,558	
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	63.51%		63.51%	
	Percentage of shares (as a % of the total share capital of the Company)	23.19%		23.19%	

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Audited Financial results have been reviewed by the Audit Committee and approved by the Board of Directors in its meeting held on 31st March, 2009 and have been audited by the Statutory Auditors of the Company.
- 3 During the quarter 4600 tons capacity of Gelatin was fully operationalised
- 4 The Board has recommended 50% Dividend (Rs. 0.50 per equity share of Re1/- each) subject to approval of members at the ensuing Annual General Meeting.
- 5 During the Quarter the Company has issued 4,039,355 equity shares of Re.1/- each pursuant to conversion of FCCBs.
- 6 The number of investor complaints for the quarter ended on 31st December, 2008 were : Openging - 3, Received - 13, Disposed off - 14, and Balance - 2.
- 7 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of  
**STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 31st March 2009

**Nitin J. Sandesara**  
**Chairman & Managing Director**